Pipeline
cu106
CU106
Expanded indication of CU06 for Immuno-Oncology Combination Therapy
| 구분 | 내용 |
|---|---|
| CU106 | Expanded indication of CU06 for Immuno-Oncology Combination Therapy |
| Indication | Immuno-Oncology Combination Therapy |
| Unmet Needs | • Immune checkpoint inhibitors have been shown to be only effective against certain types of cancer such as melanoma, lung cancer, colorectal cancer, and liver cancer. • Immuno-suppression created by the abnormal TME (tumor microenvironment) vasculature cannot be modified by anti-PD-1 therapy. • Vascular stabilization may increase the efficacy of immunotherapy by normalizing blood vessel perfusion. |
| Mechanism of Action | • Improves anti-PD1 delivery through normalized tumor vessels and promotes tumor apoptosis. • Reduces hypoxia and increases CD8+ T-cell infiltration that kills tumor cells within the central region of the tumor. • Improves tumor vascular normalization and decreases uncontrolled tumor angiogenesis. |
| Efficacy & Safety | • Improvement in tumor vascular normalization and hypoxia • Enhancing the function of tumor infiltration CD8+ T cells decreases uncontrolled tumor angiogenesis |
| Market | • By 2025, Immuno-Oncology drugs are expected to account for $56 billion, or 25% of the total oncology drug market. |
Indication
Cause
- • TME (tumor microenvironment) is a major cause of tumor progression and treatment resistance.
• TME changes are strongly associated with abnormalities in tumor vessels, including reduced vascular density and structurally disordered expansion.
Cause
- • TME (tumor microenvironment) is a major cause of tumor progression and treatment resistance.
• TME changes are strongly associated with abnormalities in tumor vessels, including reduced vascular density and structurally disordered expansion.
Unmet Needs
- • Immune checkpoint inhibitors have been shown to be only effective against certain types of cancer such as melanoma, lung cancer, colorectal cancer, and liver cancer.
• Immuno-suppression created by the abnormal TME vasculature cannot be modified by anti-PD-1 therapy.
• Vascular stabilization may increase the efficacy of immunotherapy by normalizing blood vessel perfusion.
- • Immune checkpoint inhibitors have been shown to be only effective against certain types of cancer such as melanoma, lung cancer, colorectal cancer, and liver cancer.
• Immuno-suppression created by the abnormal TME vasculature cannot be modified by anti-PD-1 therapy.
• Vascular stabilization may increase the efficacy of immunotherapy by normalizing blood vessel perfusion.
Mechanism of Action
- • Improves tumor vascular normalization and decreases hypoxia and vascular leakage by maintaining vessel structure.
• Enhances the trafficking of anti-PD1 into tumor central region via normalized tumor vessels leading to the expansion of tumor infiltrated lymphocytes within central tumor region.
• Improved TME maximizes T-cell recruitment and activation, which increases anti-tumor response.
- • Improves tumor vascular normalization and decreases hypoxia and vascular leakage by maintaining vessel structure.
• Enhances the trafficking of anti-PD1 into tumor central region via normalized tumor vessels leading to the expansion of tumor infiltrated lymphocytes within central tumor region.
• Improved TME maximizes T-cell recruitment and activation, which increases anti-tumor response.
Efficacy
Development
Ongoing Study : IL-2 agonist and CU106 combination mouse model
- • Purpose: To investigate whether CU106 is effective in improving the side-effects of IL-2-induced vascular leak syndrome (VLS)
- • Expected results: CU106 decreases the side effects by IL-2 agonist treatment and enhances the IL-2 induced anti-tumor
Ongoing Study : IL-2 agonist and CU106 combination mouse model
- • Purpose: To investigate whether CU106 is effective in improving the side-effects of IL-2-induced vascular leak syndrome (VLS)
- • Expected results: CU106 decreases the side effects by IL-2 agonist treatment and enhances the IL-2 induced anti-tumor